TOT BIOPAHRM International Company Limited is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies.
Our mission is to build a leading brand name of oncology treatments trusted by patients and their families as well as medical professionals in China. We have a comprehensive portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs, targeting various types of cancers.
Since our inception in 2009, we have built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and proven sales and marketing capabilities, which provides flexibility and scalability for our business to expand along the innovative drug industry value chain.
TOT BIOPHARM (Stock Code: 1875.HK) was successfully listed on the Main Board of Stock Exchange of Hong Kong Limited on 8 Nov 2019, which marks an important step towards accessing the international capital markets.
|Registered Office||Level 54,Hopewell Centre,No.183 Queen's Road East,Wanchai,Hong Kong|
|Headquarters and Principal Place of Business in the PRC||120 Changyang Street, Suzhou Industrial Park, Suzhou, the PRC|
|Joint Company Secretaries||Mr. Yao, Jau-Chang (姚朝昶先生) Mr. Lui, Wing Yat Christopher (呂穎一先生)|
|Authorized Representatives||Dr. Liu, Jun (刘军博士) Mr. Lui, Wing Yat Christopher (呂穎一先生)|
|Legal Advisers||Sullivan & Cromwell (Hong Kong) LLP|